Sustiva (Efavirenz) Tablets & Capsules, 600 mg and 50, 100 & 200 mg respectively, Bristol-Myers Squibb NDA 20-972/S-18 & 21-360/S-3 6/10/03 7/8/03 7/8/03 Sustiva (Efavirenz) Tablets & Capsules, 600 mg and 50, 100 & 200 mg respectively, Bristol-Myers Squibb NDA 20-972/S-19 & 21-360/S-4 6/10/03 7/8/03 7/8/03 Sustiva (Efavirenz) Tablets & Capsules, 300 & 600 mg and 50, 100 & 200 mg respectively, Bristol-Myers Squibb NDA 20-972/S-17 & 21-360/S-1 9/20/02 9/27/02 Sustiva (Efavirenz) Tablets, 300 & 600 mg, Bristol-Myers Squibb Pharma Company NDA 21-360 2/1/02 2/27/02 2/4/02 5/15/02 Sustiva (efavirenz) Capsules, 50, 100 & 200 mg, Bristol-Myers Squibb Company NDA 20-972/S-016 1/29/03 2/12/03 2/13/03 Sustiva (efavirenz) Capsules, 50, 100 & 200 mg, DuPont Company NDA 20-972/S13 10/16/01 04/25/03 Sustiva (efavirenz), Bristol-Myers Squibb Company NDA 20-972/S-007 3/1/02 3/5/02 Sustiva (efavirenz), 50mg, 100mg, 200mg capsules (Group Leader Memo) (Divison Director Memo) DuPont Company NDA 20-972 9/17/98 9/24/98 9/17/98 12/10 Sustiva (efavirenz), 50 mg, 100 mg, and 200 mg capsules DuPont Company NDA 20-972/SE7-001 2/9/00 2/14/00 Sustiva Indication:For the treatment of HIV-1 infection Sustiva (Efavirenz) Capsules & Tablets, Bristol-Myers Squibb